Pharma giant on new Nordic headquarters: This is why we chose Copenhagen
Japan's second largest pharmaceutical company wants to establish itself in the North, where an unknown number of employees based in Copenhagen will spearhead the company's Nordic advance.
Copenhagen's strong life science environment and central placement in the North was the deciding factor that made the global pharmaceutical company Daiichi Sankyo choose the Danish capital as its base for its advancement in the Nordic countries, explains Patrik Grandits, Managing Director and Head of Commercial Operations for Oncology at Daiichi Sankyo Europe to MedWatch.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
